Sanofi has shared data from the phase 3 HERCULES trial that could rescue its multiple sclerosis (MS) drug candidate ...

A federal jury in California has found that Axonics’ neurostimulators and electric leads for treating incontinence do not run ...

In this morning’s readout from Novo's phase 2 trial of monlunabant in 243 people with obesity and metabolic syndrome, it ...

Warren Biddle hit the exit from his role as SVP, global head of commercial at Gilead’s CAR-T unit Kite Pharma to take on the ...

Masimo’s long-running proxy fight has come to a close, at least for now. | Masimo’s long-running proxy fight has come to a ...

Vanda Pharmaceuticals has failed to persuade the FDA to approve its gastroparesis candidate on the strength of a phase 3 ...

Novo Nordisk is continuing its push into genetic medicines, agreeing to pay NanoVation Therapeutics up to $600 million to ...

Edgewise Therapeutics's hypertrophic cardiomyopathy (HCM) asset has started off with a bang after early safety data sent the ...

Novo Nordisk isn’t done with the RNA deals, this time penning a $530 million biobucks deal to work with Korro Bio on two ...

Slow enrollment in a key clinical trial has driven Genfit to rework the protocol to try to keep the study on track. | Slow ...

A surgeon makes small incisions in the eye, sucks out the cloudy lens and replaces it with an artificial lens implant.

Achilles Therapeutics has torn up its strategy. The British biotech is stopping work on its clinical-phase cell therapy, ...